Drotaverine (hydrochloride)

• UNSPSC Description:

  Drotaverine hydrochloride is a type 4 cyclic nucleotide phosphodiesterase (PDE4) inhibitor and an L-type voltage-dependent calcium channel (L-VDCC) blocker, blocks the degradation of 3',5'-cyclic adenosine monophosphate. Drotaverine (hydrochloride) exhibits in vivo antispasmodic efficacy without anticholinergic effects.

• Target Antigen:

  Calcium Channel; Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease;Neuronal Signaling

• Applications:

  Metabolism-protein/nucleotide metabolism

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/drotaverine-hydrochloride.html

• Purity:

  99.65

• Solubility:

  DMSO : 62.5 mg/mL (ultrasonic;warming;heat to 60°C)|H2O : 100 mg/mL (ultrasonic)

• Smiles:

  CCOC1=CC2=C(C=C1OCC)CCN/C2=C\C3=CC=C(OCC)C(OCC)=C3.[H]Cl

• Molecular Weight:

  433.97

• References & Citations:

  [1]Patai Z, Guttman A, Mikus EG. Assessment of the Airway Smooth Muscle Relaxant Effect of Drotaverine. Pharmacology. 2018;101(3-4):163-169. |[2]Zsuzsanna Tömösközi, et al. Drotaverine interacts with the L-type Ca(2+) channel in pregnant rat uterine membranes. Eur J Pharmacol. 2002 Aug 2;449(1-2):55-60.|[3]Samra Nazir, et al. Drotaverine Inhibitor of PDE4: Reverses the Streptozotocin Induced Alzheimer's Disease in Mice. Neurochem Res. 2021 Jul;46(7):1814-1829.|[4]Athanas D. Kristev, et al. Comparing hyoscine and drotaverine effects on colon in CT colonography. Cent. Eur. J. Med.6(2) . 2011 . 234-242|[5]Ioana Z Pavel, et al. Drotaverine - a Concealed Cytostatic!.Arch Pharm (Weinheim). 2017 Jan;350(1).

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  Launched

• CAS Number:

  985-12-6